PatientsVille.com Logo

Surgery and Amlodipine

PatientsVille

Surgery Symptoms and Causes

There are many reasons to have Surgery. Some operations can relieve or prevent pain. Others can reduce a symptom of a problem or improve some body function. Some surgeries are done to find a problem. For example, a surgeon may do a biopsy, which involves removing a piece of tissue to examine under a microscope. Some surgeries, like heart Surgery, can save your life.

Some operations that once needed large incisions (cuts in the body) can now be done using much smaller cuts. This is called laparoscopic Surgery. Surgeons insert a thin tube with a camera to see, and use small tools to do the Surgery.

After Surgery there can be a risk of complications, including infection, too much bleeding, reaction to anesthesia, or accidental injury. There is almost always some pain with Surgery.

Agency for Healthcare Research and Quality

Check out the latest treatments for surgery

surgery treatment research studies

Amlodipine clinical trials, surveys and public health registries


Find Drug Side Effect reports



Amlodipine Side Effects

Completed Suicide (579)
Hypotension (551)
Dizziness (380)
Overdose (356)
Oedema Peripheral (347)
Fatigue (302)
Nausea (302)
Headache (295)
Toxicity To Various Agents (295)
Dyspnoea (276)
Renal Failure Acute (271)
Rash (241)
Blood Pressure Increased (225)
Malaise (215)
Hypertension (213)
Shock (212)
Suicide Attempt (212)
Vomiting (210)
Intentional Overdose (205)
Asthenia (183)
Metabolic Acidosis (146)
Diarrhoea (143)
Joint Swelling (142)
Bradycardia (129)
Arthralgia (123)
Fall (122)
Pain (116)
Myalgia (116)
Syncope (114)
Palpitations (113)
Pruritus (108)
Cough (108)
Feeling Abnormal (107)
Somnolence (105)
Product Substitution Issue (105)
Muscle Spasms (105)
Loss Of Consciousness (105)
Pain In Extremity (102)
Death (96)
Anxiety (95)
Chest Pain (94)
Blood Pressure Inadequately Controlled (94)
Confusional State (91)
Renal Failure (90)
Condition Aggravated (88)
Angioedema (87)
Lethargy (87)
Insomnia (84)
Abdominal Pain (84)
Pneumonia (83)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

STAPHYLOCOOCUS /MRSA CURE , contact babyfaceworldk@yahoo.com phone = +2348058782330 What is staphylococcus ? Staphylococcus aureus, often referred to simply as 'staph,' are bacteria commonly carried on the s

2oo8 i caught MRSA while having spine surgery. Since than I have had many health problems. I had many antibotics, PICC LINE and more antibotics. I have been on antibotics off and on since my surgery,and a wound from the surgery that has reo

5 months suffering difficulty in breathing through the noes after taking more than 1 year ago, .Pigmentation starts to show on both leg front leg and at the ankle.My BP is 130/82 but is always fluatuate sometime below 120/70.My doctor asked me to ta

:( alas, tried it for one month and not good!. main problems, bloating, abdominal discomfort, reflux/heartburn,[had to try sleep sitting up], symptoms went on stopping, returned on restart, did lower my BP but too high a cost!.

After 2 months taking Amlopipine i developed double vision, went away when I reduced dosage, any one have anything similar.

After surgery I was unable to urinate because of blood clots, had to wear a catheter for several days and then had to have it reinsereted for a brief period of time. After about a month my flow all but stopped. After examination w

After taking Amlodipine 10mg for a year or so, can it then cause itching on the upper body; arms, back, and ribs?

After taking Amlodipine for 300 years, my d!ck fell off

Amlodpine is a dihydropyridine group Ca channel blocker usually prescribed to controll hypertension (Males) or prinz metal angina (Females) trade names Norvasac Quvasac ..... Ca channels are universally present in our b

Any advice please? Legs & ankles have swollen up terribly. Am I safe to stop them for a while. Weekend and can't get to the Doctor.

In Oct. 2010 I had a penile implant surgery. One month to the day it was removed because of infection. I have had 3 1/2 month that I wouldn't wish on anyone. It's now 4 months later and the Dr. tells me he wouldn't a

I HAD TOTAL KNEE REPLACEMENT ON JUNE 3. 2009. I HAVE BEEN IN PAIN AND STILL SEEING MY DOCTOR , WHO TOLD ME MY KNEE HAD NOT HEALED YET.SECOND OPINION DOCTOR TOLD ME THE DEVICE WAS LOOSE AND I WOULD NEED A SECOND SURGERY. IS THE

Hello my name is Violet and I'm new here. My mother had heart surgery about 8 years ago and they replaced one of her valves. About a week ago she went in for a heart ecko and they are now saying that her valve is starting to back flush. They really

<b>Describe Your Lovenox Experience Here:</b>I had hip surgery and is rapid heat beat and hearing your heart beating in your ears a side effect

10 years ago i was in the hospital for appendix surgery was given morphine it knocked me out and when i was awake i was paranoid, crying, and felt like something was wrong with my head but could not explain it it was like nothing i ever felt before.

2oo8 i caught MRSA while having spine surgery. Since than I have had many health problems. I had many antibotics, PICC LINE and more antibotics. I have been on antibotics off and on since my surgery,and a wound from the surgery that has reo

2x after the surgery the silicone was pushing out. is this common. i haditrepaired 1x now it is comming out again same location another surgery is 8/30

54y/o, WM, Status post quadruple coronary artery bypass graft surgery(10 months ago). Surgery went well, only complication was a pretty large left pleural effusion requiring chest tube placement. Resolved well, no further problems

A friend of mine has cancer and the doctors are talking about having surgery and removing the sciatica nerve. My question is will he be a function with this removal.

After 2 and half months of taking boniva i devoped severe shoulder pain that cause tendonitis and bursitis and abnormal bone formation and will have to have surgery now to inprove my pain i have been in severe pain for 5 months now boniva side eff

Surgery Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Not yet recruiting CKD-330 Drug-Drug Interaction Study (Amlodipine)
Condition: Hypertension
Interventions: Drug: Amlodipine 10mg;   Drug: Amlodipine 10mg/Candesartan 32mg
Outcome Measures: AUCτ,ss of Amlodipine;   Cmax,ss of Amlodipine;   Tmax,ss of Amlodipine
2 Recruiting Relative Bioavailability Study of One Amlodipine 10mg Tablet and One Rosuvastatin 20mg Tablet to Two Fixed Dose Combinations of Amlodipine (10mg) and Rosuvastatin (20mg) in Healthy Subjects Under Fasting Conditions
Condition: Hypertension
Interventions: Drug: Amlodipine+Rosuvastatin;   Drug: GSK3074477 FDC - 1;   Drug: GSK3074477 FDC - 2
Outcome Measures: Plasma pharmacokinetics (PK) parameters of Amlodipine and rosuvastatin following single dose administration;   Additional PK parameters of Amlodipine and rosuvastatin following single dose administration;   Safety as assessed by adverse events;   Safety as assessed by vital signs;   Safety as assessed by clinical laboratory safety data;   Safety as assessed by Electrocardiogram (ECG) parameters
3 Not yet recruiting Study of the Efficacy and Safety of LCZ696 Alone and in Combination With Amlodipine in Patients With Hypertension
Condition: Hypertension
Interventions: Drug: LCZ696;   Drug: Amlodipine;   Drug: LCZ696 and Amlodipine combination;   Drug: Placebo
Outcome Measures: Change from baseline in mean sitting systolic blood pressure (msSBP) of LCZ696 monotherapy compared to placebo;   Change from baseline in mean sitting systolic blood pressure (msSBP) of the combination of LCZ696 and Amlodipine compared to LCZ696 and Amlodipine alone.;   Change from baseline in mean sitting Diastolic Blood Pressure (msDBP) of LCZ696 monotherapy compared to placebo;   Change from baseline in mean sitting Diastolic Blood Pressure of the combination of LCZ696 and Amlodipine compared to LCZ696 and Amlodipine alone;   Change from baseline in pulse pressure;   Change from baseline in mean 24-hour ambulatory Systolic Blood Pressure of LCZ696 monotherapy compared to placebo;   Change from baseline in mean 24-hour ambulatory Diastolic Blood Pressure of LCZ696 monotherapy compared to placebo;   Change from baseline in mean daytime ( > 6am and ≤ 10 pm) ambulatory Systolic Blood Pressure of LCZ696 monotherapy compared to placebo;   Change from baseline in mean daytime ( > 6am and ≤ 10 pm) ambulatory Diastolic Blood Pressure of LCZ696 monotherapy compared to placebo;   Change from baseline in mean nighttime (> 10 pm and ≤ 6 am) ambulatory Systolic Blood Pressure of LCZ696 monotherapy compared to placebo;   Change from baseline in mean nighttime (> 10 pm and ≤ 6 am) ambulatory Diastolic Blood Pressure of LCZ696 monotherapy compared to placebo;   Change from baseline in trough to peak ratio of mean 24-hour ambulatory Systolic Blood Pressure of LCZ696 monotherapy compared to placebo;   Change from baseline in trough to peak ratio of mean 24-hour ambulatory Diastolic Blood Pressure of LCZ696 monotherapy compared to placebo;   Change from baseline in mean 24-hour ambulatory Systolic Blood Pressure of the combination of LCZ696 and Amlodipine compared to LCZ696 and Amlodipine alone;   Change from baseline in mean 24-hour ambulatory Diastolic Blood Pressure of the combination of LCZ696 and Amlodipine compared to LCZ696 and Amlodipine alone;   Change from baseline in mean daytime ( > 6am and ≤ 10 pm) ambulatory Systolic Blood Pressure of the combination of LCZ696 and Amlodipine compared to LCZ696 and Amlodipine alone;   Change from baseline in mean daytime ( > 6am and ≤ 10 pm) ambulatory Diastolic Blood Pressure of the combination of LCZ696 and Amlodipine compared to LCZ696 and Amlodipine alone;   Change from baseline in mean nighttime (> 10 pm and ≤ 6 am) ambulatory Systolic Blood Pressure of the combination of LCZ696 and Amlodipine compared to LCZ696 and Amlodipine alone;   Change from baseline in mean nighttime (> 10 pm and ≤ 6 am) ambulatory Diastolic Blood Pressure of the combination of LCZ696 and Amlodipine compared to LCZ696 and Amlodipine alone;   Percentage of patients achieving msSBP <140 mmHg and msDBP <90 mmHg;   Percentage of patients achieving msSBP <140 mmHg or a reduction ≥20 mmHg from baseline;   Percentage of patients achieving msDBP <90 mmHg or a reduction ≥10 mmHg from baseline;   Number of patients reporting adverse events
4 Not yet recruiting Fixed Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension
Condition: Hypertension
Interventions: Drug: Bisoprolol/Amlodipine (Bisoprolol sub-group A);   Drug: Bisoprolol/Amlodipine (Bisoprolol sub-group B);   Drug: Bisoprolol/Amlodipine (Amlodipine sub-group A);   Drug: Bisoprolol/Amlodipine (Amlodipine sub-group B)
Outcome Measures: Mean reduction of systolic blood pressure (SBP) after 18 weeks of treatment from Baseline (latest SBP before study treatment);   Change from Baseline (latest diastolic blood pressure [DBP] before study treatment) in DBP after 18 weeks of treatment;   Percentage of subjects with controlled blood pressure under different dosages of after study treatment;   Change from Baseline (latest heart rate [HR] before study treatment) in HR after 18 weeks treatment;   Number of subjects with adverse events (AEs)
5 Not yet recruiting Bedtime Administration of Amlodipine Versus Lisinopril
Condition: Hypertension
Intervention: Drug: Amlodipine
Outcome Measures: Change in mean sleep-time systolic blood pressure after addition of a bedtime dose of Amlodipine versus lisinopril;   Changes in mean sleep-time diastolic, awake systolic and diastolic blood pressures, including comparison of % achieving target BP;   Impact of individual medications on sleep-time blood pressure drop (dipping status);   Association of baseline renin levels to sleep-time blood pressure drop;   Association of baseline renin levels with response to Amlodipine versus lisinopril;   Association of baseline dipping status with response to Amlodipine versus lisinopril;   Association of age and response to Amlodipine versus lisinopril
6 Recruiting Amlodipine for Myocardial Iron in Thalassemia
Condition: Thalassemia
Interventions: Drug: Deferasirox or Deferoxamine or Combination (Deferoxamine and Deferiprone);   Drug: Amlodipine
Outcome Measures: Efficacy of Amlodipine in retarding rate of myocardial iron deposition (Assessed by change in T2* times);   Effect of Amlodipine therapy on left ventricular size, systolic and diastolic function;   Efficacy of Amlodipine in retarding liver iron content (mg/g);   Adverse effects of Amlodipine therapy
7 Recruiting Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine
Condition: Essential Hypertension
Interventions: Drug: Amlodipine-FA tablet,low dose group;   Drug: Amlodipine-FA tablet,high dose group;   Drug: Amlodipine
Outcome Measures: Combined effective rate of blood pressure and plasma homocysteine reduction;   Blood pressure reduction or plasma homocysteine reduction
8 Recruiting Efficacy of Amlodipine-folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine
Condition: Essential Hypertension
Interventions: Drug: Amlodipine;   Drug: Amlodipine-FA tablet, low dose group;   Drug: Amlodipine-FA tablet ,high dose group
Outcome Measures: Combined effective rate of blood pressure and plasma homocysteine reduction;   Blood pressure reduction or plasma homocysteine reduction
9 Recruiting Amlodipine Plus/Minus Atorvastatin for Protection of Arteries
Condition: Arterial and Arteriolar Disorders
Interventions: Drug: Amlodipine plus atorvastatin (Caduet);   Drug: Amlodipine (Norvasc)
Outcome Measures: flow-mediated dilation (FMD);   pulse wave velocity (cf-PWV, ba-PWV);   liver function;   ankle-brachial index (ABI);   augmentation index (AIx);   carotid intima-media thickness (IMT);   cholesterol level
10 Recruiting DMTA07 Combine With Amlodipine Treatment in Patients With Hypertension
Condition: Hypertension
Interventions: Drug: AM 5 + DM 0;   Drug: AM 5 + DM 2.5;   Drug: AM 5 + DM 7.5;   Drug: AM 5 + DM 30
Outcome Measures: *SBP reduction=SBP each visit- SBPvisit2;   The secondary objectives of the study include: Efficacy/Safety
11 Recruiting A Phase 2 Dose Selection Trial of Candesartan Cilexetil and Amlodipine Besylate to Treat Essential Hypertension
Condition: Essential Hypertension
Interventions: Drug: Amlodipine 5mg;   Drug: Amlodipine 10mg;   Drug: Candesartan Cilexetil 8mg;   Drug: Candesartan cilexetil 16mg
Outcome Measures: Change in sitting Diastolic Blood Pressure (siDBP) at week 8 compared to baseline;   Change in sitting Systolic Blood Pressure (siSBP) at week 4 and 8;   Change in siDBP at week 4;   Proportion of patients achieving ΔsiDBP > 10 mmHg and ΔsiSBP < 20 mmHg after 8 weeks;   Proportion of patients achieving siDBP < 90 mmHg and siSBP < 120 mmHg after 8 weeks
12 Recruiting Comparision of Blood Pressure Variability Between Amlodipine and Losartan
Condition: Hypertension
Interventions: Drug: Amlodipine;   Drug: Losartan
Outcome Measures: SD of visit-to-visit systolic blood pressure variability;   Central systolic blood pressure;   Augmentation index of central blood pressure;   Standard deviation of within-visit systolic blood pressure variability;   Coefficient of variation of visit-to-visit systolic blood pressure variability;   Variation independent of the mean of visit-to-visit systolic blood pressure variability;   24-h ambulatory blood pressure monitoring;   Home systolic blood pressure
13 Not yet recruiting Efficacy and Safety of TELMINUVO to Stage 2 Hypertension
Condition: Hypertension
Interventions: Drug: TELMINUVO Tab. (80/2.5mg);   Drug: TELMINUVO Tab. (80/5mg);   Drug: S-Amlodipine 2.5mg;   Drug: S-Amlodipine 5mg
Outcome Measures: Mean Sitting Systolic Blood Pressure (MSSBP);   Mean Sitting Diastolic Blood Pressure (MSDBP);   Control Rate;   Response Rate
14 Recruiting Drug-drug Interaction Study (Telmisartan, Amlodipine, Chlorthalidone)
Condition: Hypertension
Interventions: Drug: Telmisartan;   Drug: Amlodipine;   Drug: Chlorthalidone
Outcome Measures: AUCt ss, Cmax ss of telmisartan/Amlodipine/chlorthalidone;   Cmin ss, tmax ss, t1/2 of telmisartan/Amlodipine/chlorthalidone
15 Unknown  A Pilot Study Exploring Efficacy and Safety of Amlodipine in the Stented Angina Patients
Condition: Coronary Artery Disease
Interventions: Drug: Placebo;   Drug: Amlodipine
Outcome Measures: Exercise capacity;   Sublingual Nitrate;   Biomarkers
16 Recruiting Fimasartan/Amlodipine Combination Phase III
Condition: Essential Hypertension
Interventions: Drug: Fimasartan and Amlodipine;   Drug: Fimasartan
Outcome Measures: Change of Sitting Systolic Blood Pressure(SiSBP) at week 8 of Investigational Product(IP) Administration from the Baseline;   Change of Sitting Systolic Blood Pressure(SiSBP) at week 4 of Investigational Product(IP) Administration from the Baseline;   Changes of Sitting Diastolic Blood Pressure(SiDBP) at week 4 and 8 of Investigational Product(IP) Administration from the Baseline;   Response rate of the Blood Pressure at week 8 of Investigational Product(IP) Administration;   The Normalization ratio of Blood Pressure at week 8 of Investigational Product(IP) Administration
17 Recruiting Pharmacodynamic Effects of Ranolazine Versus Amlodipine on Platelet Reactivity
Condition: Coronary Artery Disease
Interventions: Drug: Ranolazine;   Drug: Amlodipine
Outcome Measures: Assessment of platelet reaction units;   Frequency of high platelet reactivity
18 Recruiting A Randomized, Double-Blind, Placebo-Controlled, 3x3 Factorial Design, Phase II Study to Evaluate the Antihypertensive Efficacy and Safety of Combination of Fimasartan and Amlodipine in Patients With Essential Hypertension
Condition: Hypertension
Intervention: Drug: Fimasartan , Amlodipine, Placebo
Outcome Measures: Sitting Diastolic Blood Pressure;   Sitting Systolic Blood Pressure;   Responder ratio
19 Unknown  Amlodipine in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major
Conditions: Thalassemia;   Iron Overload
Intervention: Drug: Amlodipine
Outcome Measures: Myocardial T2* values (msec);   Liver T2* values (msec);   Serum ferritin levels;   left ventricle volumes and function
20 Recruiting Intermittent Hypoxia 2: Cardiovascular and Metabolism
Conditions: Hypoxia;   Sleep Apnea;   Obstructive Sleep Apnea
Interventions: Drug: Placebo;   Drug: Valsartan;   Drug: Amlodipine
Outcome Measures: Change in sympathetic activity;   Measure of adrenergic, inflammatory and metabolic markers in adipose tissues by chronic intermittent hypoxia versus placebo in healthy nonobese subjects.;   Measure variations in parameters of inflammation in adipose tissue by chronic intermittent hypoxia versus placebo in healthy nonobese subjects.;   Measure of metabolic aspects of the OGTT test.;   Measure the activation of systemic inflammation by chronic HI versus placebo in healthy nonobese subjects. The systemic inflammation will be assessed in non-stress and during the OGTT.;   Assessing markers implicated in the pathophysiology of chronic metabolic diseases after HI versus placebo in healthy nonobese subjects during OGTT.;   Change in vascular responsivness;   Change in Sympathetic and vascular determinant of Blood pressure